237 related articles for article (PubMed ID: 6976793)
21. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
22. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders.
Kessler CM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):10-4. PubMed ID: 15190517
[TBL] [Abstract][Full Text] [Related]
23. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of specific thrombotic accidents in patients with thrombocytosis.
Randi ML; Fabris F; Tison T; Barbone E; Rossi C; Girolami A
Haematologia (Budap); 1993; 25(3):149-52. PubMed ID: 8119627
[TBL] [Abstract][Full Text] [Related]
25. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
[TBL] [Abstract][Full Text] [Related]
26. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia.
van Genderen PJ; Michiels JJ
Presse Med; 1994 Jan; 23(2):73-7. PubMed ID: 8140075
[TBL] [Abstract][Full Text] [Related]
27. [THE MYELOPROLIFERATIVE SYNDROME FROM THE VIEWPOINT OF CLINICAL HEMATOLOGISTS].
KUNZ G
Z Gesamte Inn Med; 1964 Dec; 19():SUPPL:194-7. PubMed ID: 14235899
[No Abstract] [Full Text] [Related]
28. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
29. Polycythaemia vera and essential thrombocythaemia in the elderly.
van Genderen PJ; Troost MM
Drugs Aging; 2000 Aug; 17(2):107-19. PubMed ID: 10984199
[TBL] [Abstract][Full Text] [Related]
30. Thrombocytosis in children.
Chiarello P; Magnolia M; Rubino M; Liguori SA; Miniero R
Minerva Pediatr; 2011 Dec; 63(6):507-13. PubMed ID: 22075805
[TBL] [Abstract][Full Text] [Related]
31. Pseudohyperkalaemia is a common finding in myeloproliferative disorders that may lead to inappropriate management of patients.
Ong YL; Deore R; El-Agnaf M
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e151-7. PubMed ID: 19016918
[TBL] [Abstract][Full Text] [Related]
32. Livedo reticularis with thrombocythaemia in association with polycythaemia rubra vera.
Clarke J; Wells GC
Br J Dermatol; 1976 Jul; 95 Suppl 14():63-4. PubMed ID: 1084155
[No Abstract] [Full Text] [Related]
33. A review of myeloproliferative disease with presentation in the head and neck region.
Collins A
Ann R Australas Coll Dent Surg; 1998 Oct; 14():119-24. PubMed ID: 10895623
[TBL] [Abstract][Full Text] [Related]
34. [MYELOPROLIFERATIVE DISORDERS].
MARCIACQ ALTAFULLA
Arch Med Panamenos; 1963 Aug; 12():149-59. PubMed ID: 14164997
[No Abstract] [Full Text] [Related]
35. Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases).
Randi ML; Stocco F; Rossi C; Tison T; Girolami A
J Med; 1991; 22(4-5):213-23. PubMed ID: 1787383
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
37. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
38. Thrombocytosis, thrombocythaemia and iron deficiency in patients with polycythaemia vera.
Shaw D; Tudhope GR
Acta Haematol; 1979; 62(4):223-8. PubMed ID: 119415
[TBL] [Abstract][Full Text] [Related]
39. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states.
Martinez J; Shapiro SS; Holburn RR
Blood; 1973 Jul; 42(1):35-46. PubMed ID: 4736876
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
